ATRYS HEALTH, S.A. financials
ATRYS HEALTH, S.A.
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
959800HHEE9W4TZA8627 Financial statements
(EUR, as reported — unscaled; 111 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €212.7M | €201.6M |
| Employee benefits expense | €85.2M | €80.6M |
| Raw materials & consumables used | €72.7M | €64.3M |
| Depreciation & amortisation | €29.0M | €29.7M |
| Operating profit (EBIT) | -€10.6M | -€1.8M |
| Net finance income / (cost) | -€22.9M | -€31.9M |
| Finance costs | €23.5M | €33.4M |
| Profit before tax | -€33.5M | -€33.7M |
| Income tax expense | -€1.6M | -€2.9M |
| Profit for the year | -€32.0M | -€45.9M |
| — attributable to owners | -€31.8M | -€45.6M |
| — attributable to NCI | -€232.0K | -€307.0K |
| Total comprehensive income | -€36.7M | -€46.9M |
| Per share | ||
| Basic EPS | €-0.42 | €-0.60 |
| Diluted EPS | €-0.42 | €-0.60 |
| Free cash flow / share | €-0.02 | €-0.01 |
| Cash flow statement | ||
| Net cash from operating activities | €3.0M | €5.7M |
| Net cash from investing activities | -€13.0M | €395.0K |
| Purchase of PP&E (capex) | €4.2M | €6.2M |
| Purchase of intangibles | €8.9M | €6.9M |
| Net cash from financing activities | -€11.5M | €1.4M |
| Proceeds from borrowings | €12.3M | €1.5M |
| Repayments of borrowings | €7.9M | €2.7M |
| Balance sheet | ||
| Total assets | €584.2M | €629.0M |
| Non-current assets | €495.0M | €528.1M |
| Property, plant & equipment | €29.5M | €30.7M |
| Right-of-use assets | €28.6M | €31.8M |
| Intangible assets & goodwill | €424.1M | €450.5M |
| Current assets | €89.2M | €100.9M |
| Trade & other receivables | €51.4M | €44.8M |
| Cash & equivalents | €20.4M | €41.8M |
| Total equity | €253.2M | €289.9M |
| Non-controlling interests | €143.0K | €10.0K |
| Non-current liabilities | €231.2M | €235.5M |
| Lease liabilities (non-current) | €25.5M | €27.0M |
| Current liabilities | €99.8M | €103.6M |
| Lease liabilities (current) | €5.8M | €6.4M |
| Trade & other payables | €25.4M | €22.3M |
| Deferred tax liabilities | €32.5M | €35.5M |
| Derived metrics | ||
| Free cash flow | -€1.3M | -€547.0K |
| Operating margin | -5.0% | -0.9% |
| Net margin | -15.0% | -22.8% |
| Return on equity | -12.6% | -15.8% |
| Cash conversion ratio | -0.09× | -0.12× |
| Capex coverage | 0.71× | 0.91× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | €21.0K | €462.0K |
| Adjustments For Decrease Increase In Other Current Assets | €197.0K | €447.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | €7.4M | -€358.0K |
| Adjustments For Depreciation and Amortisation Expense | €29.0M | €29.7M |
| Adjustments For Fair Value Gains Losses | -€1.3M | €0 |
| Adjustments For Finance Costs | €23.5M | €33.4M |
| Adjustments For Finance Income | €469.0K | €627.0K |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -€18.3M | -€683.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €417.0K | €5.5M |
| Adjustments For Increase Decrease In Other Current Liabilities | €92.0K | €1.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€2.8M | -€561.0K |
| Adjustments For Provisions | €286.0K | €350.0K |
| Adjustments For Reconcile Profit Loss | €63.2M | €67.4M |
| Comprehensive Income Attributable To Noncontrolling Interests | -€232.0K | -€307.0K |
| Comprehensive Income Attributable To Owners of Parent | -€36.4M | -€46.6M |
| Current Financial Assets | €8.9M | €3.6M |
| Current Government Grants | €316.0K | €408.0K |
| Current Loans Received and Current Portion of Noncurrent Loans Received | €14.3M | €13.4M |
| Current Prepaid Expenses | €1.4M | €1.2M |
| Current Provisions | €903.0K | €422.0K |
| Current Tax Assets Current | €2.6M | €4.2M |
| Current Tax Liabilities | €7.1M | €8.4M |
| Deferred Tax Assets | €9.6M | €9.8M |
| Dividends Recognised As Distributions To Owners of Parent | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €0 | €39.0K |
| Equity and Liabilities | €584.2M | €629.0M |
| Finance Income | €469.0K | €627.0K |
| Gains Losses Arising From Difference Between Previous Carrying Amount and Fair Value of Financial Assets Reclassified As Measured At Fair Value | €1.3M | €0 |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -€1.2M | -€39.0K |
| Income Taxes Paid Refund Classified As Operating Activities | -€705.0K | €2.2M |
| Increase Decrease In Cash and Cash Equivalents | -€21.5M | €7.5M |
| Increase Decrease In Working Capital | -€6.6M | -€1.1M |
| Increase Decrease Through Disposal of Subsidiary | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €60.0K | €7.0K |
| Increase Decrease Through Transfers and Other Changes Equity | -€2.0K | €114.0K |
| Increase Decrease Through Treasury Share Transactions | -€27.0K | €287.0K |
| Inflows of Cash From Investing Activities | €385.0K | €39.7M |
| Interest Paid Classified As Operating Activities | €21.2M | €25.3M |
| Interest Received Classified As Operating Activities | €469.0K | €627.0K |
| Investment Accounted For Using Equity Method | €1.0K | €13.0K |
| Issue of Convertible Instruments | €3.0K | €4.0K |
| Issued Capital | €760.0K | €760.0K |
| Miscellaneous Other Operating Expense | €28.7M | €31.1M |
| Miscellaneous Other Operating Income | €1.1M | €479.0K |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €2.9M | €3.5M |
| Noncurrent Financial Assets | €3.2M | €5.3M |
| Noncurrent Government Grants | €1.2M | €6.7M |
| Noncurrent Portion of Noncurrent Loans Received | €151.8M | €148.4M |
| Noncurrent Provisions | €1.0M | €2.7M |
| Other Adjustments To Reconcile Profit Loss | -€779.0K | -€1.1M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€4.7M | -€973.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€4.7M | -€973.0K |
| Other Current Financial Liabilities | €45.8M | €51.8M |
| Other Inflows Outflows of Cash Classified As Operating Activities | -€20.1M | -€26.9M |
| Other Noncurrent Financial Liabilities | €18.6M | €14.4M |
| Other Work Performed By Entity and Capitalised | €5.4M | €4.5M |
| Outflows of Cash From Investing Activities | €13.3M | €39.3M |
| Proceeds From Issue of Bonds Notes and Debentures | €4.8M | €13.0M |
| Profit Loss From Continuing Operations | -€31.8M | -€30.8M |
| Profit Loss From Discontinued Operations | -€160.0K | -€15.1M |
| Purchase of Financial Instruments Classified As Investing Activities | €200.0K | €2.1M |
| Repayments of Bonds Notes and Debentures | €24.0M | €0 |
| Reserve of Exchange Differences On Translation | -€7.9M | -€3.3M |
| Revenue From Government Grants | €5.8M | €421.0K |
| Share Premium | €420.1M | €420.1M |
| Treasury Shares | €323.0K | €293.0K |
Methodology
Every line item above is a fact tagged in ATRYS HEALTH, S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.